RC48 plus AK104 for HER2-positive advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of two drugs (RC48 and AK104) as the first treatment for advanced HER2-positive stomach cancer. The goal is to see if this combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Your cancer must be HER2-positive (a score of 2+ or 3+ on a special test).
- You should not have had any prior chemotherapy for advanced cancer, unless it was given before surgery and more than 6 months ago.
- You need to be in good physical shape (able to do daily activities on your own).
- Your organs (like kidneys, liver, heart, and bone marrow) must be working well, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—RC48 (a targeted therapy), sintilimab (an immunotherapy), and S-1 (a chemotherapy pill)—as a first treatment for advanced HER2-positive stomach cancer that has not been treated before. The goal is to see if this triple therapy works better than current options.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a new drug called RC48 combined with chemotherapy for people with HER2-positive advanced breast cancer that has worsened after treatment with a specific type of antibody-drug conjugate (a drug that targets cancer cells). The goal is to see if this new combination can help when other treatments have stopped working.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Hear when a new HER2-positive Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.